Human immunodeficiency virus and solid organ transplantation: a 15‐year retrospective audit at a tertiary Australian transplant centre

• Published in: Internal medicine journal Vol. 52; no. 10; pp. 1780 - 1790
• Main Authors: Griffin, David W. J., Kotecha, Sakhee, Basu, Gopal, Gow, Paul, Lau, Jillian S. Y., Morrissey, Catherine O., Hoy, Jennifer F.
• Format: Journal Article
• Language: English
• Published: Melbourne John Wiley & Sons Australia, Ltd 01-10-2022; Wiley Subscription Services, Inc
• Subjects: Antiretroviral therapy; CD4 antigen; chronic kidney disease; chronic liver disease; chronic lung disease; Comorbidity; Graft rejection; HIV; Human immunodeficiency virus; Immune system; Lung transplantation; Patients; solid organ transplantation; Transplants & implants; human immunodeficiency virus; chronic liver disease; chronic lung disease; solid organ transplantation; chronic kidney disease; antiretroviral therapy
• ISSN: 1444-0903; 1445-5994
• DOI: 10.1111/imj.15423

Background
The incidence of end‐stage organ disease in people living with human immunodeficiency virus (HIV) (PLWH) is increasing, as people live longer due to potent, tolerable antiretroviral therapy (ART). Consequently, the number of PLWH who would benefit from solid organ transplant (SOT) is rising. The SOT experience in PLWH in Australia remains limited.
Aim
To retrospectively review the outcomes for SOT in PLWH at our service, in Victoria, Australia.
Methods
A retrospective cohort study of PLWH undergoing SOT over a 15‐year period was performed. Adult PLWH age >18 years were eligible and identified from the Victorian HIV Service database. Descriptive statistics were used to summarise baseline demographics and clinical data, and outcomes following SOT.
Results
Nine virologically suppressed PLWH underwent SOT from HIV‐negative donors (five kidneys, two livers and two bilateral sequential lung transplants). All patients were male, with a median age of 57.3 years (interquartile range (IQR) = 54.3–60.1) and CD4 count of 485 (IQR = 342–835) at transplantation, and comorbidities were common at baseline. After a median follow up of 3.9 years (IQR = 2.7–7.6), 8 (89%) patents were alive, 7 (78%) had functioning grafts, although 5 (56%) experienced organ rejection. Infections were common. Two patients required modification to their ART due to significant drug−drug interactions prior to transplant, while 5 (56%) had modifications post‐SOT. No patients experienced HIV virologic failure.
Conclusion
PLWH with end‐stage organ disease experience good clinical and functional outcomes and should be considered for SOT where indicated. However, multidisciplinary planning and care is essential to optimise care in this patient group.